Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Newly Augmented Microdispenser System Replaces Five Liquid Handling Instruments

By BiotechDaily International staff writers
Posted on 13 Apr 2014
Image: The MultiFlo FX Multi-Mode Dispenser with the BioStack 4, for lidded or unlidded plates (Photo courtesy of Biotek Instruments, Inc.).
Image: The MultiFlo FX Multi-Mode Dispenser with the BioStack 4, for lidded or unlidded plates (Photo courtesy of Biotek Instruments, Inc.).
Upgrades to a highly regarded microdispenser system allows the instrument fo replace up to five separate liquid handlers, saving operator time and instrumentation costs

The new BioTek (Winooski, VT, USA) MultiFlo FX Microplate Dispenser is now available with optional RAD (Random Access Dispense) technology to further extend its application range and flexibility. RAD technology offers single-channel dispensing to random individual microplate wells along with rapid reagent dispensing into large volume wells of 6- to 24-well microplates. MultiFlo FX can also be separately configured with an optional wash module for 6- to 384-well plates.
The Multiflo FX accommodates microplate types ranging from 6- to 1536-wells, and dispenses volumes of from one to three microliters accurately and precisely. BioTek's proprietary angled dispensing ensures compatibility with all dispense protocols including media exchanges with loosely adherent cell monolayers. For assays requiring minimum reagent usage, the MultiFlo's prime volume is less than one milliliter. A built-in priming trough is designed to allow both recovery of reagents or to send primed reagent directly to waste.

MultiFlo FX was especially designed for sensitive cell-based assays, ELISAs, and bead-based assays, with angled dispense tips and flexible flow rates to maintain cell integrity.

Due to its small footprint and base height of less than 20.3 cm, the MultiFlo FX readily fits on any laboratory bench or robotic system. It is easily integrated with the BioTek BioStack Microplate Stacker, allowing up to 75 plates to be dispensed automatically. Simplified programming via intuitive on-board software and a color touch screen display enable control of dispense patterns, and two integrated USB ports provide convenient file transfer and storage options.

“Microplate-based bulk dispensing can be complex, especially in an automated system,” said Jason Greene, BioTek product manager. “We specifically designed MultiFlo FX to streamline this process, providing more value through multitasking, and time savings.”

Related Links:
BioTek



Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.